Praxis Precision Medicines (PRAX) Could Be 49% Undervalued As Patch Deal Expands Ulixacaltamide Reach

Simply Wall St.07-20

Praxis Precision Medicines (PRAX) drew fresh investor attention after announcing a research collaboration and license agreement with Remagine Labs to develop a multi day iontophoretic transdermal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652261765?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-20 11:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652261765","market":"sg","top_or_hot":-1,"title":"Praxis Precision Medicines (PRAX) Could Be 49% Undervalued As Patch Deal Expands Ulixacaltamide Reach","media":"Simply Wall St.","content":"<div>\n<p>Praxis Precision Medicines (PRAX) drew fresh investor attention after announcing a research collaboration and license agreement with Remagine Labs to develop a multi day iontophoretic transdermal ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-could-be-49-undervalued-as-p\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines (PRAX) Could Be 49% Undervalued As Patch Deal Expands Ulixacaltamide Reach</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines (PRAX) Could Be 49% Undervalued As Patch Deal Expands Ulixacaltamide Reach\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-20 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-could-be-49-undervalued-as-p><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Praxis Precision Medicines (PRAX) drew fresh investor attention after announcing a research collaboration and license agreement with Remagine Labs to develop a multi day iontophoretic transdermal ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-could-be-49-undervalued-as-p\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-could-be-49-undervalued-as-p","article_id":"2652261765","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-could-be-49-undervalued-as-p","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652261765","pubTimestamp":1784518237,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Praxis Precision Medicines (PRAX) drew fresh investor attention after announcing a research collaboration and license agreement with Remagine Labs to develop a multi day iontophoretic transdermal patch for ulixacaltamide in essential tremor.\nSee our latest analysis for Praxis Precision Medicines.\nThe latest collaboration news arrives after a period of mixed momentum for Praxis Precision Medicines, with the share price up 11.37% over 30 days but down 8.22% over 90 days, while the 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4139":"生物科技","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IBRN":"iShares Neuroscience and Healthcare ETF","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","PRAX":"Praxis Precision Medicines, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"由于补丁协议扩大了Ulixacaltamide的覆盖范围，Praxis Precision Medicines (PRAX) 的估值可能被低估 49%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1.5,"IBRN":0.6},"content_text":"Praxis Precision Medicines (PRAX) drew fresh investor attention after announcing a research collaboration and license agreement with Remagine Labs to develop a multi day iontophoretic transdermal patch for ulixacaltamide in essential tremor. See our latest analysis for Praxis Precision Medicines. The latest collaboration news arrives after a period of mixed momentum for Praxis Precision Medicines, with the share price up 11.37% over 30 days but down 8.22% over 90 days, while the 1 year total shareholder return is very large and the 3 year total shareholder return is more than 18x, which may indicate strong longer term sentiment. If you are interested in other CNS and biotech stories harnessing new delivery or AI tools in healthcare, it could be worth scanning 39 healthcare AI stocks. Praxis Precision Medicines now sits at the crossroads of a rich CNS pipeline, new delivery technology plans and a share price that has already delivered very large 1 year gains. How is that package actually being valued today? AdvertisementMost Popular Narrative: 49.1% Undervalued On the most followed narrative, Praxis Precision Medicines is priced well below its fair value estimate of $617.67 versus the last close at $314.41. This hinges on a set of ambitious earnings and margin assumptions over the coming years.  Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.  Read the complete narrative. Want to understand why this fair value sits so far above today’s price? The narrative leans on rapid revenue build, rising margins and a premium future earnings multiple, all tied to a small group of CNS assets reaching scale. The exact mix of growth rates, profitability and share count behind that view might surprise you. Result: Fair Value of $617.67 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this Praxis Precision Medicines narrative could be quickly tested if key epilepsy trials underperform or if vormatrigine development faces further delays and study changes. Find out about the key risks to this Praxis Precision Medicines narrative. Next Steps With mixed signals around Praxis Precision Medicines so far, it makes sense to review the full picture quickly and build your own view using the company’s 2 key rewards and 2 important warning signs. Looking for more investment ideas beyond Praxis Precision Medicines? If Praxis Precision Medicines has sharpened your interest, do not stop here. Use the screeners below to quickly surface fresh ideas that fit different investing styles.  Spot potential value opportunities early by reviewing companies flagged in the 47 high quality undervalued stocks. Prioritize resilience by focusing on businesses highlighted in the 82 resilient stocks with low risk scores. Hunt for potential future standouts by checking the screener containing 20 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652261765","isCrawlerRequest":true}